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Inhaled corticosteroid therapy for asthma is used increasingly from a pre-school age. Current knowledge of 
adverse systemic effects, however, is based on treatment of older children. Eighteen asthmatic children aged 
4.5-7.4 years who had taken budesonide by Nebuhaler in doses averaging 20&l IOOpg mm2 day-’ during the 
previous year were studied. Height velocities calculated over this period were no different from those of the 
normal population. Neither the velocities nor a modest delay in bone ages were related to budesonide dose. Every 
child responded normally to tetracosactrin. These young asthmatic children do not show a greater susceptibility 
to systemic effects from an inhaled corticosteriod than older counterparts. 
Introduction 
Treatment of very young asthmatic children with 
inhaled corticosteroids (ICS) is now facilitated by 
large volume spacer devices. Increasing numbers of 
pre-school asthmatic children are being treated in this 
way. Studies of systemic effects from ICS however, 
have generally been in asthmatics old enough to use 
conventional inhalers and include few children below 
the age of 7 years. They show preservation of long- 
term growth and dynamic adrenal function with doses 
up to 800 pug day ’ (I ,2) and a dose-dependent fall in 
basal cortisol secretion (3). Presuming the same in 
earlier childhood needs verification. The relatively 
rapid growth during this period may put these children 
at greater risk of growth inhibition from ICS than the 
older children studied in the past. 
The aim of this study was to determine whether a 
group of children, typical of the younger asthmatics 
now receiving ICS, had grown normally during a year 
of continuous treatment. A measure of each child’s 
adrenal reserve was also made. 
Patients and Methods 
PATIENTS 
Eighteen consecutive asthmatic children attending 
the Respiratory Clinic who were taking budesonide by 
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Nebuhaler were studied. Their current ages ranged 
from 4.5 to 7.4 (median 5.6) years (Table 1). 
Budesonide had been started 1348 (median 25) 
months previously because of failed prophylaxis with 
sodium cromoglycate or theophylline, and/or chest 
deformity due to asthma. Doses had been 400 pg day-’ 
initially, and in the range 200-8OOpg day-’ sub- 
sequently, except in Patient 18 (1200 pg day- ’ briefly) 
and Patient 1 (1OOpg day-’ on occasions). No child 
was on regular oral steroids. No short courses of pred- 
nisolone for acute asthma attacks had been given 
within 11 weeks of the study day. Every child used the 
Nebuhaler proficiently. Compliance had been checked 
34 monthly. All children were prepubertal at the time 
of study. 
METHODS 
Standing height was measured to the nearest mm 
on a stadiometer by one of four outpatient nurses 
proficient with the method. Measurements made 0.9- 
1.3 (median 1.1) yr before, on the same apparatus by 
the same personnel, were obtained from the clinic 
records retrospectively to calculate height velocities. 
Each velocity was related to the normal population (4) 
as a standard deviation (SD) score, which was the dif- 
ference between an observed value and the 50th centile 
value for age, divided by the standard deviation at this 
age. 
To allow for budesonide dose changes during the 
velocity period, an average dose was calculated which 
weighted different doses according to their duration. 
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Table I Patient data, budesonide treatment details, current height centiles and results of tetracosactrin stimulation tests 
Patient 
No. Sex 
Age 
(years) 
Budesonide Treatment 
Serum cortisol 
Current Corrected (nmoll-‘) 
Duration dose dose Height 
(months) ,ug m-* day-’ pg rn-? day-’ centile Basal Increment 
1 F 5.4 30 127 201 46 120 650 
2 F 66 26 196 303 100 120 450 
3 M 5.9 23 455 369 94 150 430 
4 F 6.3 39 366 389 47 140 430 
5 M 7.4 47 430 455 12 130 690 
6 M 6.0 29 476 471 46 540 310 
7 M 64 39 460 491 85 290 330 
8 M 4.7 16 706 504 100 140 490 
9 M 5.9 27 506 519 63 260 460 
10 F 4.9 17 533 559 75 230 350 
11 M 5.1 22 533 559 59 250 490 
12 M 4.8 26 541 571 56 170 320 
13 M 5.1 14 519 635 67 640 340 
14 F 6.5 48 682 719 72 230 600 
15 M 5.0 18 1039 722 83 120 480 
16 M 5.9 13 741 764 58 200 340 
17 F 5.2 19 857 815 16 190 440 
18 M 5.8 29 952 1104 63 320 540 
Patients numbered in order of increasing ‘corrected budesonide dose’, which was the dose averaged over the previous year. Age, 
height centile and serum cortisol refer to current data. 
This weighted average was divided by the mean of the 
body surface area (5) at the beginning and end of the 
velocity period. The resultant corrected dose (Table 
1) gave the best estimation of budesonide exposure 
during the period of velocity assessment. 
Current radiographs of the left wrist were obtained. 
An experienced observer determined RUS bone ages 
(TW2 method) in which the radius, ulnar and 18 other 
bones were individually rated (6). Bone ages were 
expressed as SD scores using population data based on 
the Tanner and Whitehouse standards (6). 
A short tetracosactrin test was performed in each 
child. The morning budesonide was omitted and blood 
drawn between 09.00 h and 10.00 h for basal cortisol 
level. Two hundred and fifty micrograms of tetraco- 
sactrin (Synacthen) were given intravenously and a 
second sample taken 30min later. Serum cortisol 
was determined by a solid-phase 12’1 radioimmuno- 
assay (Coat-A-Count@ Cortisol, Diagnostic Products 
Corporation). A normal response was defined as a 
two-fold or greater rise in serum cortisol, an increment 
of at least 200nmolll’ or a peak of at least 
500 nmol ll’. 
The study had been approved by the hospital’s 
ethical committee and informed parental consent was 
obtained. 
STATISTICAL ANALYSIS 
Height velocity and bone age SD scores were 
expressed as means with 95% confidence intervals. 
Correlations were assessed by Spearman’s rank 
correlation coefficient. 
Results 
The height velocity range was within approximately 
2 SD of the 50th centile. The mean height velocity SD 
score was f0.11 with 95% CI from -0.38 to +0.60 
(Fig. 1). There was no significant correlation between 
height velocity SD score and corrected budesonide 
dose. 
The mean bone age SD score was -0.68 with 95% CI 
- 1.05 to -0.31. No child had a bone age delayed 
more than 2 SD from the 50th centile (Fig. 1). Bone age 
SD score did not correlate with corrected budesonide 
dose. 
Basal morning serum cortisol levels ranged from 120 
to 640 (median 195) nmol ll’ (Table 1). Six children 
had levels below 150nmol 1-l but there was no 
correlation between morning cortisol and corrected 
budesonide dose, nor with current dose or duration of 
treatment. All children showed normal responses to 
tetracosactrin (Table 1). The cortisol increment ranged 
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Fig. 1 Height velocity (HtVel) and bone age (BnAge) standard deviation scores (SDS). Mean and 95% confidence intervals are 
indicated. 
from 310 to 690 (median 445) nmol 1-l and did not 
vary with any of the treatment parameters mentioned. 
Discussion 
The present study centred on an age when height 
velocity was still relatively high and growth assessment 
would not be complicated by variability in pubertal 
growth spurts. 
The distribution of height velocities was representa- 
tive of the normal population. Over the age range of 4- 
7 years in both girls and boys height velocity standard 
deviations are very similar, being about 1 cm yr-‘. 
The mean SD score in the study, + 0.1, therefore corre- 
sponded to a velocity only 0.1 cm yr-’ higher than the 
population mean. Similarly, the 95% CI corresponded 
to f0.5 cm yr-I. This interval was regarded to be 
narrow enough to give clinical validity to the absence 
of a statistical difference between the study sample and 
the normal population, without the need for a larger 
study. 
Children who had had budesonide dose adjustments 
during the period of velocity assessment were not 
excluded. This ensured that a full range of treated 
children were represented, rather than only those 
with stable asthma. Dose changes have usually been 
ignored in previous studies. They may have been less 
frequent than in the present young children in whom 
the minimum therapeutic dose may not have been 
determined. The lack of correlation between height 
velocity SD score and corrected budesonide dose 
supported the absence of an effect on growth. 
The population mean bone age SD score, 0, was 
outside the 95% CI for the study group. The group 
therefore had delayed bone age with respect to TW 
standards statistically. No bone age was more than 2 
SD below the 50th centile. The mean and 95% CI 
corresponded to a small delay of 0.7 f 0.4 yr, as the SD 
of RUS bone age was about 1 yr in this age range (6). 
This finding cannot be ascribed to budesonide with- 
out a further study. However, if the therapy were 
implicated a correlation between dose and skeletal 
maturation might be expected. This was not found. 
Furthermore delayed skeletal maturation is a recog- 
nized feature of asthma (7). Regardless of the expla- 
nation, the significance of the modest bone age delay 
would appear to be more statistical than clinical in the 
face of slightly above average height centile (Table 1) 
and normal average height velocity. 
Six children had somewhat low morning cortisol 
levels. A dose-dependent suppression in resting cortisol 
secretion from ICS even in conventional dosage is well 
documented (3) and might be expected in the present 
age group as well. However the morning cortisol is at 
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best a rough screening test for adrenal hypofunction 
indicating the need for more definitive testing. The lack 
of relation between basal morning cortisol levels and 
budesonide dose, probably reflects the unreliability of 
the former as a measure of basal secretion. 
The current vogue for demonstrating negative 
feedback inhibition of basal cortisol output in sera (3) 
and urine (8) by ICS should not be confused with a 
demonstration of adrenal insufficiency. Certainly when 
ICS impair responses to tetracosactrin there is an as- 
sociated reduction in 24-h urinary freecortisol excretion 
(9). However it is not clear whether subtle falls in basal 
secretion always indicate a risk, or even impending risk 
of adrenal crisis should ICS be suddenly withdrawn or 
major stress occur, or whether they may simply reflect a 
physiological adjustment to avert corticosteroid excess 
from systemically absorbed ICS with no risk to the 
hypothalamo-pituitary-adrenal axis. A dynamic test 
was therefore preferred in this study. 
Every child had a normal adrenal reserve judged by 
standard tetracosactrin stimulation. This test has been 
used to monitor recovery from steroid suppression 
(IO) as cortical recovery usually occurs after the pitu- 
itary, although in this capacity it is less reliable than 
insulin stress testing. The latter is unpleasant however 
and can be hazardous. Standard tetracosactrin stimu- 
lation can certainly reveal adrenal impairment in 
adults taking high dose (> 1000 c(g daily) ICS (9). 
The present data showed that young asthmatics grew 
normally during a year of treatment with budesonide 
in average doses of 200-I 100 ,ug m-’ dayy’. A minor 
bone age delay was unlikely to be related to ICS 
therapy. Adrenal reserve was intact in every child on 
pharmacological testing. These very young asthmatic 
children do not therefore appear to have a greater 
susceptibility to adverse effects from ICS than their 
older counterparts. 
Finally it should be emphasized that the children 
were all using large volume spacer devices which have 
been shown to decrease the systemic influence of very 
high doses of ICS (I I). Indeed the present conclusions 
cannot be applied to children using higher doses of 
budesonide. Nor do they preclude the need for con- 
tinued surveillance during ICS treatment in view of the 
possibility of rare idiosyncratic systemic effects (12). 
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